Evaluation of CUR-1916 in the patients with Dravet Syndrome.
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
Price : $35 *
At a glance
- Drugs CUR 1916 (Primary)
- Indications Dravet syndrome
- Focus Adverse reactions
- Sponsors OPKO Health
- 08 Aug 2017 According to an OPKO Health media release, company plans to to file an IND for this trial and expected to begin this study by the end of 2017.
- 22 Mar 2017 According to an OPKO Health media release, this trial is expected to initiate in 2017.
- 16 Mar 2017 New trial record